Second Amendment to License Agreement between Recro Pharma, Inc. and Cornell University
This document is a second amendment to the License Agreement between Recro Pharma, Inc. and Cornell University, represented by its Center for Technology Licensing. The amendment, effective as of the last signature date in November 2018, modifies specific due diligence requirements in the original agreement. All other terms and conditions remain unchanged. The amendment is signed by authorized representatives of both parties.
Exhibit 10.26
[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.
|
| 395 Pine Tree Road, Suite 310 Ithaca, New York 14850 p- 607 ###-###-#### f. 607 ###-###-#### www.ctl.cornell.edu |
October 31, 2018
Jyrki Mattila, PhD
Executive Vice President of Business Development
Recro Pharma, Inc.
490 Lapp Road, Malvern PA 19355
Email: ***@***
RE:AMENDMENT
to the License Agreement by and between Recro Pharma, Inc. (hereinafter “LICENSEE”) and Cornell University (“Cornell”), as represented by its Center for Technology Licensing at Cornell University (hereinafter “CTL”) effective June 30, 2017, and amended effective October 24, 2017 (Cornell Contract #C2017-12-10946)
Effective as of the date of the last signature below (“Second Amendment Date”), the undersigned parties agree to hereby modify the License Agreement referenced above as follows:
1)In Paragraph 3.3 Due Diligence, replace (a)(ii) and (a)(iii) with the following:
(ii) [***];
(iii) [***];
2)These changes do not otherwise change the terms and conditions of the Agreement.
|
|
|
|
IN WITNESS THEREOF, the parties have caused this instrument to be executed in duplicate as of the Amendment Date written above.
| Cornell University |
| Recro Pharma, Inc. | ||||
|
|
|
|
|
|
|
|
| By: |
| /s/ Brian J. Kelly, PhD |
| By: |
| /s/ G. A. Henwood |
|
|
|
|
|
|
|
|
| Name: |
| Brian J. Kelly, PhD |
| Name: |
| G.A. Henwood |
| Title: |
| Director, Technology Licensing |
| Title: |
| CEO & President |
|
|
|
|
|
|
|
|
| Date: |
| November 29, 2018 |
| Date: |
| November 27, 2018 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
